Pediatric unipolar depression and pharmacotherapy: General principles
- C Scott Moreland, DO
C Scott Moreland, DO
- Clinical Assistant Professor
- Baylor College of Medicine
- Liza Bonin, PhD
Liza Bonin, PhD
- Associate Professor of Pediatrics and Psychiatry
- Baylor College of Medicine
- Section Editors
- David Brent, MD
David Brent, MD
- Section Editor — Childhood Mental Disorders
- Professor of Psychiatry, Pediatrics and Epidemiology
- University of Pittsburgh School of Medicine
- Diane Blake, MD
Diane Blake, MD
- Section Editor — Adolescent Medicine
- Professor of Pediatrics
- University of Massachusetts Medical School
There are several general principles for prescribing pharmacotherapy to children and adolescents with unipolar depression. Following these principles may improve outcomes [1-3].
This topic reviews the general principles of administering pharmacotherapy to pediatric patients with depressive disorders. Choosing a drug and the efficacy of antidepressants in depressed youth is discussed separately, as are psychosocial treatments for adolescent depression, an overview of treating pediatric depression, and the effect of antidepressant medications on suicide risk in children and adolescents.
- Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46:1503.
- Martin A, Scahill L, Charney DS, Leckman JF. Pediatric Psychopharmacology: Principles and Practice, Martin A (Ed), Oxford University Press, New York 2003. p.288.
- Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management. Pediatrics 2007; 120:e1313.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
- The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. http://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on September 27, 2012).
- Kutcher S, Gardner D, Virani A. A clinical approach to treating Major Depressive Disorder with SSRIs in Adolescents: 12 steps to careful monitoring. Child Adolesc Psychopharmacol News 2004; 9:1.
- Hagman, J. Diagnosis and treatment of depression in adolescence. Adolescent Health Update 2001; 13:1.
- Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.
- Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; 11:CD004851.
- Le Noury J, Nardo JM, Healy D, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351:h4320.
- Varigonda AL, Jakubovski E, Taylor MJ, et al. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:557.
- Heiligenstein JH, Hoog SL, Wagner KD, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol 2006; 16:207.
- Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 2011; 31:92.
- Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193:10.
- Lewandowski RE, Acri MC, Hoagwood KE, et al. Evidence for the management of adolescent depression. Pediatrics 2013; 132:e996.
- Labeling change request letter for antidepressant medications. Available at: www.fda.gov/cder/drug/antidepressants/SSRIlabelChange.htm (Accessed on March 24, 2008).
- Lock J, Walker LR, Rickert VI, et al. Suicidality in adolescents being treated with antidepressant medications and the black box label: position paper of the Society for Adolescent Medicine. J Adolesc Health 2005; 36:92.
- American Academy of Child and Adolescent Psychiatry. Supplementary talking points for child and adolescent psychiatrists regarding the FDA black box warning on the use of antidepressants for pediatric patients, November 2004. Available at: www.aacap.org/galleries/PsychiatricMedication/BlackBoxTalkingPoints.pdf (Accessed on March 24, 2008).
- Richardson LP, McCauley E, McCarty CA, et al. Predictors of persistence after a positive depression screen among adolescents. Pediatrics 2012; 130:e1541.
- Joinson C, Heron J, Araya R, Lewis G. Early menarche and depressive symptoms from adolescence to young adulthood in a UK cohort. J Am Acad Child Adolesc Psychiatry 2013; 52:591.
- Sund AM, Larsson B, Wichstrøm L. Prevalence and characteristics of depressive disorders in early adolescents in central Norway. Child Adolesc Psychiatry Ment Health 2011; 5:28.
- Wood A, Kroll L, Moore A, Harrington R. Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. J Child Psychol Psychiatry 1995; 36:327.
- Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901.
- Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459.